357 related articles for article (PubMed ID: 20347506)
1. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Treat J; Edelman MJ; Belani CP; Socinski MA; Monberg MJ; Chen R; Obasaju CK;
Lung Cancer; 2010 Dec; 70(3):340-6. PubMed ID: 20347506
[TBL] [Abstract][Full Text] [Related]
2. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
Treat JA; Gonin R; Socinski MA; Edelman MJ; Catalano RB; Marinucci DM; Ansari R; Gillenwater HH; Rowland KM; Comis RL; Obasaju CK; Belani CP;
Ann Oncol; 2010 Mar; 21(3):540-547. PubMed ID: 19833819
[TBL] [Abstract][Full Text] [Related]
3. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L
J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Ansari RH; Socinski MA; Edelman MJ; Belani CP; Gonin R; Catalano RB; Marinucci DM; Comis RL; Obasaju CK; Chen R; Monberg MJ; Treat J;
Crit Rev Oncol Hematol; 2011 May; 78(2):162-71. PubMed ID: 20413322
[TBL] [Abstract][Full Text] [Related]
5. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
Uramoto H; Nakanishi R; Nagashima A; Uchiyama A; Inoue M; Osaki T; Yoshimatsu T; Sakata H; Nakanishi K; Yasumoto K
Anticancer Res; 2010 Nov; 30(11):4695-9. PubMed ID: 21115926
[TBL] [Abstract][Full Text] [Related]
7. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
[TBL] [Abstract][Full Text] [Related]
8. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Paccagnella A; Oniga F; Bearz A; Favaretto A; Clerici M; Barbieri F; Riccardi A; Chella A; Tirelli U; Ceresoli G; Tumolo S; Ridolfi R; Biason R; Nicoletto MO; Belloni P; Veglia F; Ghi MG
J Clin Oncol; 2006 Feb; 24(4):681-7. PubMed ID: 16446341
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
Detterbeck FC; Socinski MA; Gralla RJ; Edelman MJ; Jahan TM; Loesch DM; Limentani SA; Govindan R; Zaman MB; Ye Z; Monberg MJ; Obasaju CK
J Thorac Oncol; 2008 Jan; 3(1):37-45. PubMed ID: 18166839
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer.
Beniwal SK; Patel KM; Shukla S; Parikh BJ; Shah S; Patel A
Indian J Cancer; 2012; 49(2):202-8. PubMed ID: 23107971
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Comella P; Chiuri VE; De Cataldis G; Filippelli G; Maiorino L; Vessia G; Cioffi R; Mancarella S; Putzu C; Greco E; Palmeri L; Costanzo R; Avallone A; Franco L
Lung Cancer; 2010 Apr; 68(1):94-8. PubMed ID: 19545929
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
[TBL] [Abstract][Full Text] [Related]
13. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Edelman MJ; Belani CP; Socinski MA; Ansari RH; Obasaju CK; Chen R; Monberg MJ; Treat J;
J Thorac Oncol; 2010 Jan; 5(1):110-6. PubMed ID: 20035187
[TBL] [Abstract][Full Text] [Related]
14. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.
Illiano A; Barletta E; De Marino V; Battiloro C; Barzelloni M; Scognamiglio F; Rossi N; Zampa G; De Bellis M; Gridelli C
Anticancer Res; 2000; 20(5C):3999-4003. PubMed ID: 11268491
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Soetekouw PM; Timmer-Bonte JN; van der Drift MA; van Leeuwen F; Wagenaar M; van Die L; Bussink J; Tjan-Heijnen VC
Int J Clin Oncol; 2013 Dec; 18(6):988-96. PubMed ID: 23011101
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M
Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
Greco FA; Burris HA; Hainsworth JD
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):31-4. PubMed ID: 10960943
[TBL] [Abstract][Full Text] [Related]
19. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
Quoix E; Audigier-Valette C; Lavolé A; Molinier O; Westeel V; Barlesi F; Le Treut J; Pichon E; Dauba J; Otto J; Moreau L; Madelaine J; Dumont P; Margery J; Debieuvre D; Renault PA; Pujol JL; Langlais A; Morin F; Moro-Sibilot D; Souquet PJ
Eur J Cancer; 2020 Oct; 138():193-201. PubMed ID: 32898792
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
